AZD2066
Sponsors
AstraZeneca
Conditions
Chronic PainDiabetic NeuropathyHealthyMajor Depressive DisorderMechanical HypersensitivityNeuropathic PainPainReflux Episodes
Phase 1
Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects
CompletedNCT00684502
Start: 2008-01-31End: 2008-11-30Updated: 2010-12-10
Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066
CompletedNCT00686504
Start: 2008-04-30End: 2008-06-30Target: 6Updated: 2010-12-10
AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers
CompletedNCT00690404
Start: 2008-04-30End: 2008-06-30Updated: 2010-12-10
Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects
CompletedNCT00766012
Start: 2008-09-30End: 2009-07-31Updated: 2009-08-25
14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations
CompletedNCT00813306
Start: 2008-12-31End: 2009-11-30Target: 40Updated: 2010-12-07
Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066
CompletedNCT00829088
Start: 2009-01-31End: 2009-02-28Updated: 2009-02-25
AZD2066 Cocktail Study
CompletedNCT00930306
Start: 2009-06-30End: 2009-09-30Updated: 2009-10-27
Phase 2
Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy
CompletedNCT00857623
Start: 2009-02-28End: 2009-08-31Updated: 2012-11-12
AZD2066 Neuropathic Pain - Mechanical Hypersensitivity
TerminatedNCT00939094
Start: 2009-08-31End: 2010-11-30Updated: 2012-09-27
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
TerminatedNCT01145755
Start: 2010-05-31End: 2010-11-30Updated: 2012-10-03